Literature DB >> 17541596

Antiovarian antibodies in primary Sjogren's syndrome.

Kyriaki Euthymiopoulou1, Alexios J Aletras, Panagiota Ravazoula, Anna Niarakis, Dimitris Daoussis, Ioannis Antonopoulos, Stamatis-Nick Liossis, Andrew P Andonopoulos.   

Abstract

Our study aimed at screening patients with primary Sjogren's syndrome (pSs) for the presence of antiovarian antibodies (AOAs). Detection of AOAs in patients' sera was achieved by ELISA, using bovine ovarian extract for coating. Western blot analysis and immunohistochemistry were used to characterize the antibody targets in the extract and to determine their locus on the bovine ovary, respectively. Specific AOAs were detected in 27% of 37 patients (two with premature menopause) and in none of the controls. Immunoreactivity mainly resided in five proteins of the extract with molecular masses 42, 49, 55, 64 and 72 kDa, and it might be attributed to their carbohydrate components. The antibody targets were mainly located in the granulosa and theca interna cells of the follicle, and in the endothelial cells and fibroblasts of corpus luteum. The detection, for the first time, of AOAs in a significant percentage of patients with pSs may suggest autoimmune oophoritis, clinical or subclinical.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17541596     DOI: 10.1007/s00296-007-0364-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  46 in total

1.  Antibodies to cytoplasm of ova.

Authors:  M B Vallotton; A P Forbes
Journal:  Lancet       Date:  1966-07-30       Impact factor: 79.321

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Immunological disturbances in patients with premature ovarian failure.

Authors:  F Pekonen; R Siegberg; T Mäkinen; A Miettinen; O Yli-Korkala
Journal:  Clin Endocrinol (Oxf)       Date:  1986-07       Impact factor: 3.478

4.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

5.  Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community.

Authors:  C Vitali; S Bombardieri; H M Moutsopoulos; G Balestrieri; W Bencivelli; R M Bernstein; K B Bjerrum; S Braga; J Coll; S de Vita
Journal:  Arthritis Rheum       Date:  1993-03

6.  Premature ovarian failure: evidence for the autoimmune mechanism.

Authors:  C B Coulam; R D Kempers; R V Randall
Journal:  Fertil Steril       Date:  1981-08       Impact factor: 7.329

7.  Pubertal progression in the presence of elevated serum gonadotropins in girls with multiple endocrine deficiencies.

Authors:  A W Lucky; R W Rebar; R M Blizzard; E M Goren
Journal:  J Clin Endocrinol Metab       Date:  1977-10       Impact factor: 5.958

8.  Ovarian failure and autoimmunity. Detection of autoantibodies directed against both the unoccupied luteinizing hormone/human chorionic gonadotropin receptor and the hormone-receptor complex of bovine corpus luteum.

Authors:  H Moncayo; R Moncayo; R Benz; A Wolf; C Lauritzen
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

9.  Prevalence of circulating antibodies directed toward ovaries among women with premature ovarian failure.

Authors:  C B Coulam; R J Ryan
Journal:  Am J Reprod Immunol Microbiol       Date:  1985-09

Review 10.  Premature ovarian failure: an update.

Authors:  J N Anasti
Journal:  Fertil Steril       Date:  1998-07       Impact factor: 7.329

View more
  2 in total

Review 1.  Sjögren syndrome.

Authors:  Clio P Mavragani; Haralampos M Moutsopoulos
Journal:  CMAJ       Date:  2014-02-24       Impact factor: 8.262

Review 2.  Early menopause: A hazard to a woman's health.

Authors:  Claudio Hernández-Angeles; Camil Castelo-Branco
Journal:  Indian J Med Res       Date:  2016-04       Impact factor: 2.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.